Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced Hematological Disorders”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT02465528
What this trial is testing

Ceritinib Rare Indications Study in ALK+ Tumors

Who this might be right for
Tumors With Aberrations in ALKAnaplastic Large Cell LymphomaInflammatory Myofibroblastic Tumor+1 more
Novartis Pharmaceuticals 22
Early research (Phase 1)Ended earlyNCT02225574
What this trial is testing

An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T)

Who this might be right for
Leukemia
M.D. Anderson Cancer Center 1
Not applicableLooking for participantsNCT07051850
What this trial is testing

Quality of Life and Treatment Outcomes in RRMM Patients Receiving Advanced vs. Conventional Immunotherapies

Who this might be right for
Multiple Myeloma, RelapsedMultiple Myeloma (MM)
Sung-Soo Park 174
Testing effectiveness (Phase 2)Study completedNCT01606579
What this trial is testing

Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies

Who this might be right for
Acute Myeloid LeukemiaChronic Myeloid Leukemia
Prism Pharma Co., Ltd. 49
Testing effectiveness (Phase 2)Study completedNCT01177397
What this trial is testing

Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma

Who this might be right for
Multiple MyelomaDiffuse Large B-Cell LymphomaGlioblastoma Multiforme+4 more
Celgene 226
Testing effectiveness (Phase 2)Study completedNCT00358020
What this trial is testing

Melphalan, Prednisone, Thalidomide And Bortezomib In Advanced And Refractory Multiple Myeloma Patients

Who this might be right for
Multiple Myeloma
University of Turin, Italy 30
Testing effectiveness (Phase 2)Ended earlyNCT02034227
What this trial is testing

Safety, Tolerability Study of SG2000 in the Treatment of Advanced Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid LeukemiaChronic Lymphocytic Leukemia
Spirogen 6
Testing effectiveness (Phase 2)Study completedNCT00823524
What this trial is testing

Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer

Who this might be right for
Brain and Central Nervous System TumorsChronic Myeloproliferative DisordersLeukemia+6 more
Asan Medical Center 47
Large-scale testing (Phase 3)Study completedNCT00003687
What this trial is testing

Treatment for Chronic Pain in Patients With Advanced Cancer

Who this might be right for
Chronic Myeloproliferative DisordersLeukemiaLymphoma+6 more
NCIC Clinical Trials Group 87
Early research (Phase 1)UnknownNCT00023816
What this trial is testing

Carbendazim in Treating Patients With Advanced Solid Tumors or Lymphoma

Who this might be right for
LymphomaUnspecified Adult Solid Tumor, Protocol Specific
Jonsson Comprehensive Cancer Center
Early research (Phase 1)Looking for participantsNCT05768932
What this trial is testing

BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

Who this might be right for
Advanced Solid TumorTNBC - Triple-Negative Breast CancerGastric Cancer+1 more
SillaJen, Inc. 260
Testing effectiveness (Phase 2)WithdrawnNCT04029038
What this trial is testing

Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma

Who this might be right for
CD19 PositiveCD22 PositiveMinimal Residual Disease+7 more
M.D. Anderson Cancer Center
Early research (Phase 1)Study completedNCT02352558
What this trial is testing

BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies

Who this might be right for
Hematologic Malignancy
Sumitomo Pharma America, Inc. 15
Early research (Phase 1)Study completedNCT00025415
What this trial is testing

Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction

Who this might be right for
Accelerated Phase Chronic Myelogenous LeukemiaAcute Undifferentiated LeukemiaAIDS-related Peripheral/Systemic Lymphoma+78 more
National Cancer Institute (NCI) 60
Early research (Phase 1)Looking for participantsNCT05488548
What this trial is testing

Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies

Who this might be right for
Castrate Resistant Prostate CancerNUT CarcinomaChronic Myelomonocytic Leukemia+1 more
Epigenetix, Inc. 75
Not applicableUnknownNCT04327583
What this trial is testing

Impact of the Coordinated Intervention of the Healthcare Facilities Pharmacist and the Dispensary Pharmacist on the Care Pathway for Cancer Patients Treated With Oral Therapy

Who this might be right for
Advanced or Metastatic Solid TumorRelapsed Hematologic Malignancy
Institut Cancerologie de l'Ouest 396
Testing effectiveness (Phase 2)Study completedNCT00588666
What this trial is testing

Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma

Who this might be right for
Myeloproliferative DisorderUrothelial CarcinomaCancer
Memorial Sloan Kettering Cancer Center 51
Early research (Phase 1)Looking for participantsNCT03816345
What this trial is testing

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

Who this might be right for
Autoimmune DiseaseCrohn DiseaseDermatomyositis+11 more
National Cancer Institute (NCI) 300
Early research (Phase 1)Study completedNCT02561988
What this trial is testing

(EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies

Who this might be right for
Aggressive Systemic MastocytosisSystemic Mastocytosis-associated Hematologic Non-mast Cell DiseaseMast Cell Leukemia+1 more
Blueprint Medicines Corporation 86
Early research (Phase 1)Ended earlyNCT03530683
What this trial is testing

A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma

Who this might be right for
LymphomaMultiple MyelomaAcute Myeloid Leukemia+1 more
Pfizer 189
Next Page